"Dec. 18, 2012 -- People who can't get their high blood pressure down with drugs may be helped by a new procedure that deactivates overactive nerves in the kidneys, a small study shows.
The procedure is already available in Europe and "...
Cardene IV Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Cardene I.V. (nicardipine hydrochloride) is indicated for the short-term treatment of high blood pressure (hypertension) for patients who cannot take the medication orally. It is a calcium channel blocker. This medication is available in generic form. Common side effects include headache, low blood pressure (hypotension), rapid heart rate (tachycardia), or nausea/vomiting.
Cardene I.V. is intended for intravenous use and dosage is individualized depending on the patient's condition and response to treatment. Cardene I.V. may interact with beta- blockers (particularly in heart failure patients), cimetidine, or cyclosporine. Tell your doctor all medications you are taking. Cardene I.V. should be used during pregnancy only if prescribed. This medication passes into breast milk. Breast-feeding while using this medication is not recommended.
Our Cardene I.V. (nicardipine hydrochloride) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Cardene IV FDA Prescribing Information: Side Effects
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.
Two hundred forty-four patients participated in two multicenter, double-blind, placebo-controlled trials of Cardene I.V. Adverse experiences were generally not serious and most were expected consequences of vasodilation. Adverse experiences occasionally required dosage adjustment. Therapy was discontinued in approximately 12% of patients, mainly due to hypotension, headache, and tachycardia.
The table below shows percentage of patients with adverse events where the rate is > 3% more common on Cardene I.V. than placebo.
|Adverse Event||Cardene I.V.
|Body as a Whole|
|Headache, n (%)||21 (15)||2 (2)|
|Hypotension, n (%)||8 (6)||1 (1)|
|Tachycardia, n (%)||5 (4)||0|
|Nausea/vomiting, n (%)||7 (5)||1 (1)|
Other adverse events have been reported in clinical trials or in the literature in association with the use of intravenously administered nicardipine:
Body as a Whole: fever, neck pain
Hemic and Lymphatic: thrombocytopenia
Metabolic and Nutritional: hypophosphatemia, peripheral edema
Nervous: confusion, hypertonia
Respiratory: respiratory disorder
Urogenital: urinary frequency
Post-Marketing And Other Clincal Experience
Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure. The following adverse reaction has been identified during post-approval use of Cardene I.V.: decreased oxygen saturation (possible pulmonary shunting).
Read the entire FDA prescribing information for Cardene IV (Nicardipine Hydrochloride)
Additional Cardene I.V. Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on handling your hypertension.